Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
Electron transport chain (ETC) dysfunction has been claimed to contribute to the expression of neurodegenerative disorders. We have investigated the effects of the treatment with rivastigmine, a commonly used cholinesterase inhibitor, on lymphocyte mitochondria of patients with Alzheimer's disease (AD). Increased enzymatic activities of diverse complexes and oxidative capacity of the ETC were found. Enhanced mitochondrial ETC function may contribute to the beneficial effects of rivastigmine on clinical manifestations of AD.
Casademont
J
J
Muscle Research Group, Internal Medicine Department, Hospital Clinic, IDIBAPS, Faculty of Medicine, University of Barcelona, Villarroel 170:08036, Barcelona, Catalonia, Spain. jordi@medicina.ub.es
Miró
O
O
Rodriguez-Santiago
B
B
Viedma
P
P
Blesa
R
R
Cardellach
F
F
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism*; D002219:Carbamates / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004579:Electron Transport / Q000187:drug effects; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D048448:Phenylcarbamates; D012016:Reference Values; D000068836:Rivastigmine
D002219:Carbamates; D002800:Cholinesterase Inhibitors; D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine